# 119-s-5316: BINSA Act

119-s-5316, BINSA Act, is a 119th Congress bill sponsored by Sen. Ricketts, Pete [R-NE] (R-NE); status introduced; PRIA reads it as touching household money (as of 2026-08-30).

- Canonical: https://policyrisk.com/legislation/119-s-5316
- As of: 2026-08-30
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Bill: 119-s-5316
- Congress: 119
- Title: BINSA Act
- Status: introduced
- Introduced: 2026-08-06
- Sponsor: Sen. Ricketts, Pete [R-NE] (R-NE)
- Cosponsors: 1
- Policy area: International Affairs
- Touches household money: yes
- Last recorded action: 2026-08-30

## Summary

**Expands Defense Production Act controls to cover biotechnology outbound licensing and investments.** The bill would tighten screening, require rulemaking on what counts as covered biotechnology, and order a near-term Defense Department assessment on capital flows to China. - U.S. biotech companies and researchers would face new limits on outbound licensing, joint ventures, and certain equity deals with covered foreign persons. The bill defines biotechnology to include pharmaceutical and biological products, therapeutic platforms, clinical development capabilities, manufacturing know‑how, and related intellectual property. - Investors and corporate planners would need to navigate a prohibited or notifiable transaction framework for cross-border biotech deals. Congress cites about $136 billion in 2025 cross-border out‑licensing between U.S./European firms and Chinese biotech firms as a motivating concern. - The Treasury Secretary must write mandatory rules, after consulting HHS, the Department of Defense, and the Director of National Intelligence, to set geographic and substantive boundaries and to exclude agricultural biotech, non‑pharma industrial fermentation, and basic academic research. The Secretary of Defense must deliver an unclassified assessment to Congress within 60 days on whether U.S. capital and licensing into China’s biotech sector threaten national security.

## Cosponsors (1)

- Sen. Slotkin, Elissa [D-MI] (D-MI), 2026-08-06T00:00:00.000Z

## Provisions PRIA read

- Tighter biotech licensing and investment rules: mixed, medium. If enacted, this bill would add "biotechnology" to the Defense Production Act's prohibited and notifiable technology lists. It would bar licensing of certain drugs, biological products, therapeutic compounds, and related know‑how to covered foreign persons, effective on enactment. It would also req…

## Related bills

- 119-s-4668: Protect College Sports Act of 2026
- 119-s-1748: Kids Online Safety Act
- 119-s-3265: Improve and Enhance the Work Opportunity Tax Credit Act
- 119-s-4456: AI OVERWATCH Act
- 119-s-2654: Biomanufacturing and Jobs Act of 2025
- 119-s-1639: American Innovation and Jobs Act

## Sources
- [119-s-5316 on Congress.gov](https://www.congress.gov/bill/119th-congress/senate-bill/5316)

## Related
- [119-s-4668: Protect College Sports Act of 2026](https://policyrisk.com/legislation/119-s-4668)
- [119-s-1748: Kids Online Safety Act](https://policyrisk.com/legislation/119-s-1748)
- [119-s-3265: Improve and Enhance the Work Opportunity Tax Credit Act](https://policyrisk.com/legislation/119-s-3265)
- [119-s-4456: AI OVERWATCH Act](https://policyrisk.com/legislation/119-s-4456)
- [119-s-2654: Biomanufacturing and Jobs Act of 2025](https://policyrisk.com/legislation/119-s-2654)
- [119-s-1639: American Innovation and Jobs Act](https://policyrisk.com/legislation/119-s-1639)
- [All bills in Congress](https://policyrisk.com/legislation)

Source: PRIA, https://policyrisk.com/legislation/119-s-5316 (as of 2026-08-30).